Mineralocorticoid Receptor Antagonists: Addressing Residual Risk in Patients with Cardiac Disease, T2DM, and CKD

Mineralocorticoid Receptor Antagonists: Addressing Residual Risk in Patients with Cardiac Disease, T2DM, and CKD is organized by Rockpointe Corporation.

Release Date: Dec 20, 2022
Expiration Date: Dec 20, 2023

Description
T2DM is the leading cause of CKD worldwide and CVD is the leading cause of morbidity and mortality for patients with T2DM and for patients with CKD. People with T2DM and CKD are at increased risk for CVD and CV death compared with those with T2DM alone. Even with optimal medical therapy, these patients remain at high risk for CVD events and progression to ESRD. MRAs are recommended for the treatment of resistant HTN and for managing HF in patients with T2DM and CKD. Lack of guidelines for the use of MRAs and fear of hyperkalemia has resulted in many eligible patients not being given MRAs, receiving them late in the disease course, and/or not receiving optimal dosing. New nonsteroidal MRAs are associated with a lower incidence of hyperkalemia and improved CKD and CVD benefits.

Mineralocorticoid Receptor Antagonists: Addressing Residual Risk in Patients with Cardiac Disease, T2DM, and CKD will provide cardiologists with information about the interrelationship of CVD and renal disease and the efficacy and safety of MRAs as well as expert guidance about the role of MRAs in the management of patients with T2DM, CKD, and CVD.

Educational Objectives
At the conclusion of this education, participants should be able to:

• Discuss the role of the mineralocorticoid receptor in the development and progression of renal and cardiovascular disease.
• Evaluate for and monitor CKD in patients with T2DM and cardiac disease.
• Assess the data for the efficacy and safety of approved mineralocorticoid receptor antagonists.
• Incorporate mineralocorticoid receptor antagonists into management plans for patients with CKD, T2DM, and cardiovascular disease.